Human KRAS Knockout Cell Line-Hela
Cat.No. : CSC-RT0518
Host Cell: Hela Target Gene: KRAS
Size: >1x10^6 cells/vial, 1 mL Validation: Sequencing
Inquire for Price
Cell Line Information
Cell Culture Information
Safety and Packaging
| Cat. No. | CSC-RT0518 |
| Cell Line Information | This cell line is a stable cell line with a homozygous knockout of human KRAS using CRISPR/Cas9. |
| Target Gene | KRAS |
| Gene ID | 3845 |
| Genotype | KRAS (-/-) |
| Host Cell | Hela |
| Cell Type | Epithelial |
| Size | >1x10^6 cells/vial, 1 mL |
| Sequencing Result | Homozygous: 1 bp insertion in exon |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Media Type | Cells were cultured in DMEM supplemented with 10% fetal bovine serum. |
| Growth Properties | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Split at 80-90% confluence, approximately 1:4-1:6. |
| Freeze Medium | Complete medium supplemented with 10% (v/v) DMSO |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Inquiry
Background
Applications
KRAS (Kirsten rat sarcoma viral oncogene homolog) is a gene that encodes a protein involved in cellular signaling. As part of the RAS oncogene family, the KRAS gene is related to the HRAS and NRAS genes and is an integral part of the MAPK/ERK signaling pathway, which mediates various cellular functions, including proliferation, survival, and growth.
Mutations in the KRAS gene are known to be associated with various types of cancer, making it one of the most studied genes in oncology. KRAS mutations are particularly common in pancreatic, colorectal, and lung cancers. In pancreatic ductal adenocarcinoma (PDAC), nearly 90% of cases exhibit KRAS mutations, making it a key target for therapeutic intervention. Similarly, approximately 40% of colorectal cancers and 15-25% of lung adenocarcinomas carry KRAS mutations. Despite the importance of KRAS, direct targeting of KRAS has been challenging due to the protein’s high affinity for GTP/GDP and lack of binding sites suitable for drug design.
Recent advances show promise, particularly the development of KRAS G12C inhibitors, which specifically target the mutant form of the protein found in certain cancers. Drugs such as sotorasib and adagrasib have shown efficacy in treating patients with KRAS G12C mutant non-small cell lung cancer, marking a major breakthrough in precision oncology.
Human KRAS knockout HeLa cell lines are valuable tools in biomedical research. Here are a few key applications of human KRAS knockout HeLa cell lines:
Cancer Research: The KRAS gene is frequently mutated in various cancers, making the KRAS knockout HeLa cell line valuable for studying oncogenic mechanisms. Researchers can study how loss of KRAS affects cell signaling, tumor growth, and metastasis, providing insights into potential therapeutic targets.
Drug Screening: These cell lines are an important tool for high-throughput screening of anticancer drugs. By evaluating the efficacy and toxicity of new compounds in KRAS knockout HeLa cells, scientists can identify drug candidates that selectively target KRAS mutant pathways.
Gene Function Studies: KRAS knockout HeLa cells enable researchers to study the role of KRAS in cellular processes such as cell proliferation, differentiation, and apoptosis.
Signal Transduction Studies: KRAS is a key player in the RAS/MAPK signaling pathway. Using knockout cell lines, researchers can dissect the complexity of the pathway and determine how KRAS interacts with other proteins and contributes to signaling, which is critical for developing pathway-specific inhibitors.
Study of Resistance Mechanisms: Cancer cells often become resistant to therapies. By using KRAS knockout HeLa cells, researchers can explore how the loss of KRAS affects resistance mechanisms.
For research use only. Not intended for any clinical use.
